DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-485/S-008
NDA 21-485/S-012

PRIOR APPROVAL SUPPLEMENT

Orion Corporation
Attention: Marguerite Coleman
Regulatory Affairs Consultant
B&H Consulting Services, Inc.
55 North Gaston Avenue
Somerville, NJ 08876

Dear Ms. Coleman:

Please refer to your supplemental new drug applications dated December 14, 2006, received December 19, 2006 (supplement 8), and dated May 24, 2007, and received May 30, 2007 (supplement 12) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Stalevo® (levodopa/carbidopa/entacapone) Tablets 200/50/200 mg.

Supplement 8 provides for the addition of information regarding intense urges to gamble, increased sexual urges, and other intense urges in patients using medications to treat Parkinson's disease. Supplement 12 provides for the addition of information regarding melanoma to the PRECAUTIONS section of the package insert.

We also refer to the teleconference between Orion, Novartis and the Division of Neurology Products on November 8, 2007, in which you agreed to add the following text to the Information for Patients subsection of the PRECAUTIONS section:

> "There have been reports of patients experiencing intense urges to gamble, increased sexual urges, and other intense urges and the inability to control these urges while taking one or more of the medications that increase central dopaminergic tone, that are generally used for the treatment of Parkinson's disease, including Stalevo. Although it is not proven that the medications caused these events, these urges were reported to have stopped in some cases when the dose was reduced or the medication was stopped. Prescribers should ask patients about the development of new or increased gambling urges, sexual urges or other urges while being treated with Stalevo. Patients should inform their physician if they experience new or increased gambling urges, increased sexual urges or other intense urges while taking Stalevo. Physicians should consider dose reduction or stopping the medication if a patient develops such urges while taking Stalevo."

We further refer to your amendment dated December 8, 2007, containing the agreed upon language, as above.

We completed our review of this application and it is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert).

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submissions "**FPL for approved supplement NDA 21-485/S-008**." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Stacy Metz, PharmD, Regulatory Project Manager, at (301) 796-2139.

Sincerely,

{See appended electronic signature page}

Russell Katz, M.D.
Director
Division of Neurology Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure (labeling)

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Russell Katz

2/2/2009 01:40:04 PM